Patents Examined by Yunsoo Kim
-
Patent number: 11701328Abstract: Compositions and methods for inducing immune tolerance to proteins and subsequence administration of the proteins are disclosed. Compositions comprise proteins complexed with liposomes comprising PS and PC, wherein at least part of the PS is present as lyso-PS.Type: GrantFiled: March 19, 2020Date of Patent: July 18, 2023Assignee: The Research Foundation for The State University of New YorkInventors: Sathy Balu-Iyer, Richard Bankert, Radha Ramakrishnan, Robert Dingman, Vandana Iyer, Jennifer Schneider, Fiona Yau Glassman, Nhan Hanh Nguyen
-
Patent number: 11696951Abstract: The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid protein formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions. The inventive methods can also yield a higher stability of a liquid protein formulation.Type: GrantFiled: October 21, 2019Date of Patent: July 11, 2023Assignee: Comera Life Sciences, Inc.Inventors: Philip Wuthrich, Robert P. Mahoney, Subhashchandra Naik, Timothy Tran, Yuhong Zeng
-
Patent number: 11696950Abstract: Described herein are dry vaccine compositions and methods of freezing aluminum-containing vaccines such that when converted into a dried powder, the dry vaccine can be readily reconstituted to form a stable liquid vaccine without significant loss of activity.Type: GrantFiled: October 10, 2018Date of Patent: July 11, 2023Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Zhengrong Cui, Robert O. Williams, III, Xinran Li
-
Patent number: 11692027Abstract: The present disclosure provides pharmaceutical compositions for monoclonal antibodies, antibody-related products, therapeutic proteins, peptides and other biopharmaceuticals. The compositions provide initial and long term stability of the biopharmaceutical agent, rendering them suitable for parenteral, pulmonary, transdermal, topical, intradermal, intrascleral, intracorneal, ocular and other forms of delivery. The compositions and methods lead to higher yields in dilute solutions and reduce unwanted aggregation of the biopharmaceutical agent. The compositions and methods also allow for disaggregation of previously aggregated proteins and protection from aggregation upon dilution. Additionally, provided are non-aggregating antibody reagents for analytical immunoassays including ELISA methods. The invention provides compositions and methods for topical, enteral, parenteral, pulmonary and other forms of delivery of biologically active substances.Type: GrantFiled: September 25, 2017Date of Patent: July 4, 2023Assignee: Board of Regents, The University of Texas SystemInventors: Edward R. Kraft, Steven Andrew Giannos, Bernard Godley
-
Patent number: 11667702Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of aflibercept, wherein the formulation is free of organic co-solvent and/or free of buffer; methods for making such a formulation; and methods of using such a formulation.Type: GrantFiled: March 8, 2019Date of Patent: June 6, 2023Assignee: Coherus Biosciences, Inc.Inventors: Jun Liu, Mark Manning
-
Patent number: 11655289Abstract: Pharmaceutical compositions containing anti-beta amyloid (A?) antibodies or AD-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of A? in the central nervous system, mild cognitive impairment, and AD-associated disorders such as Alzheimer's disease.Type: GrantFiled: August 22, 2018Date of Patent: May 23, 2023Assignee: Biogen MA Inc.Inventors: Steven Andrew Lantz, Kapil Gupta, Shantanu Sule, Adnan Zunic
-
Patent number: 11648317Abstract: The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.Type: GrantFiled: April 12, 2019Date of Patent: May 16, 2023Assignee: Genentech, Inc.Inventors: Ankit R. Patel, Jun Liu
-
Patent number: 11639391Abstract: The present invention provides a stable liquid formulation of an antibody in phosphate-amino acid based dual buffer system. The antibody formulated in phosphate-amino acid based dual buffer system imparts optimum stability to the antibody, at lower as well as higher concentrations. Further, the antibody formulated in phosphate-amino acid based buffer system has low viscosity and is suitable for therapeutic administration of high concentrations of antibody.Type: GrantFiled: April 18, 2018Date of Patent: May 2, 2023Assignee: DR. REDDY'S LABORATORIES LIMITEDInventors: Murali Jayaraman, Pravin Nair, Navneet Kaur, Deepak Thumbrahalli
-
Patent number: 11634485Abstract: Stable aqueous pharmaceutical formulations for therapeutic antibodies and methods of using such stable aqueous pharmaceutical formulations.Type: GrantFiled: February 11, 2020Date of Patent: April 25, 2023Assignee: Eli Lilly and CompanyInventors: Vincent John Corvari, Karthik Pisupati
-
Patent number: 11628217Abstract: The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.Type: GrantFiled: August 30, 2017Date of Patent: April 18, 2023Assignee: OMEROS CORPORATIONInventors: Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
-
Patent number: 11612562Abstract: An objective of the present invention is to provide stable antibody-containing formulations which are suitable for subcutaneous administration and in which aggregation formation is suppressed during long-term storage. The present inventors discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid as a counter ion species in histidine buffer or tris(hydroxymethyl)aminomethane, specifically by using histidine-aspartate buffer or histidine-glutamate buffer, or tris(hydroxymethyl)aminomethane-aspartate or tris(hydroxymethyl)aminomethane-glutamate as a buffer. The present inventors also discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid, as a counter ion species to a basic amino acid such as arginine, specifically by using arginine-aspartate or arginine-glutamate.Type: GrantFiled: June 14, 2018Date of Patent: March 28, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Chifumi Moriyama
-
Patent number: 11613570Abstract: The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.Type: GrantFiled: April 14, 2022Date of Patent: March 28, 2023Assignee: 180 THERAPEUTICS LPInventors: Jagdeep Nanchahal, Glenn R. Larsen, Marc Feldmann
-
Patent number: 11608357Abstract: There is provided, inter alia, an aqueous solution comprising (i) an antibody protein; and (ii) a antibody protein stabilizing mixture of arginine, methionine, and a C3 polyol.Type: GrantFiled: August 27, 2019Date of Patent: March 21, 2023Assignee: ARECOR LIMITEDInventors: Jan Jezek, Luca Badiali, David Gerring
-
Patent number: 11603407Abstract: The present invention provides stable pharmaceutical formulations comprising a human antibody that specifically binds to human programmed death-1 protein (PD-1). In certain embodiments, the formulations contain, in addition to an anti-PD-1 antibody, a buffer, an amino acid, a non-ionic surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.Type: GrantFiled: March 21, 2018Date of Patent: March 14, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Qingyan Hu, Dingjiang Liu
-
Patent number: 11596690Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-33 (hIL-33). The formulations may contain, in addition to an anti-IL-33 antibody, a buffer, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stresses.Type: GrantFiled: March 20, 2020Date of Patent: March 7, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Qingyan Hu, Dingjiang Liu
-
Patent number: 11590243Abstract: The present invention relates to the formulation of adenoviral vectors in sorbitol containing compositions in combination with a further amorphous sugar, its formulation as well as a method for obtaining a dried composition.Type: GrantFiled: January 25, 2018Date of Patent: February 28, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Erwan Bourles, Olivier Despas, Delphine Guillaume, Frederic Mathot, Mathieu Vasselle
-
Patent number: 11583584Abstract: The present invention is directed to compositions and methods for stabilizing a protein without a surfactant. The present invention is further directed to compositions comprising a protein and at least one excipient selected from the group consisting of hindered amines, anionic aromatics, functionalized amino acids, oligopeptides, low molecular weight aliphatic polyacids, zwitterions, phospholipids, cyclodextrins, polyethylene glycols, gelatins, urea, ethanol, glycerin, dextran, xanthan gum, 2-(2-ethoxyethoxy)ethanol, hydroxypropyl cellulose, propylene glycol, a short-chain organic acid, deoxycholate, sodium nitrate, sodium sulfate, proline and lysine.Type: GrantFiled: October 28, 2016Date of Patent: February 21, 2023Assignee: Coherus Biosciences, Inc.Inventors: Jun Liu, Mark Manning, Isaias Prado
-
Patent number: 11576970Abstract: The invention relates to a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. In addition, it relates to a method for reducing precipitation of an antibody or an antigen-binding fragment thereof in a liquid pharmaceutical formulation through addition of methionine and cyclodextrin. In particular, the liquid pharmaceutical formulations comprises an anti-sclerostin antibody, hydroxypropyl-gamma cyclodextrin and methionine and may be used in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength, and especially for treating osteoporosis.Type: GrantFiled: March 9, 2017Date of Patent: February 14, 2023Assignee: UCB BIOPHARMA SRLInventors: Andrew Jeffrey Yates, James Gregory Clipstone
-
Patent number: 11576863Abstract: The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention also relates to the reconstituted formulation obtained by the method described herein, the use of said antibody formulation as a medicament, the use of the lyophilized formulation for the preparation of a medicament and a method of treating a patient.Type: GrantFiled: March 17, 2014Date of Patent: February 14, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Markus Rast, Wolfgang Ise, Gerhard Becker, Peter Skufca, Henning Gieseler
-
Patent number: 11571383Abstract: Described are low viscosity, hypotonic formulations containing one or more proteins, e.g., antibodies, at high concentration, uses of the formulations, and articles of manufacture. In particular, the formulations are useful and beneficial for the subcutaneous administration or delivery of a high concentration of a protein drug, such as an antibody, to a subject who is afflicted with a disease or condition that is treatable by the protein drug.Type: GrantFiled: March 19, 2018Date of Patent: February 7, 2023Assignee: CytoDyn Inc.Inventor: Tracy T. Chen